ADAG logo

Adagene (ADAG) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

China

IPO:

09 February 2021

Indexes:

Not included

Website:

http://www.adagene.com

Description:

Adagene is a biotechnology company focused on developing innovative antibody-based therapies for cancer treatment. They use advanced technology to create personalized medicines that target specific cancer cells, aiming to improve patient outcomes and reduce side effects. Their goal is to enhance the effectiveness of cancer therapies.

Key Details

Price

$2.31

Market Cap

$102.27 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$18.11 M(+94.90% YoY)

Annual EPS

-$0.44(+76.35% YoY)

PE Ratio

-

Annual ROE

-24.66%

Annual Debt To Equity

0.31

Beta

0.17

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

July 25, 2024

Recent annual earnings:

Mar 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

18 Sept '24 HC Wainwright & Co.
Buy
22 July '24 HC Wainwright & Co.
Buy
28 June '24 HC Wainwright & Co.
Buy
04 Oct '23 HC Wainwright & Co.
Buy
01 Sept '23 HC Wainwright & Co.
Buy
21 Apr '23 HC Wainwright & Co.
Buy
29 Mar '23 HC Wainwright & Co.
Buy
21 Mar '23 HC Wainwright & Co.
Buy
24 Jan '23 Morgan Stanley
Overweight
07 Dec '22 HC Wainwright & Co.
Buy

Screeners with ADAG included

Small cap stocks
NASDAQ earnings calendar
Biggest stock gainers today
Stocks below SMA 200
Stocks with low beta
Stocks below analysts price target
Most recommended stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.31
ADAG price is $2.31

Price YTD Change

+23.53%
ADAG price is up +23.53% since January 1st

Price All-time High

$29.99
ADAG price is currently -92.30% below its historical high of $29.99

Price Analysts Target

$4.90
ADAG price is currently -52.86% lower than the consensus analysts' forecast

Market Cap

$102.27 M
ADAG market capitalization is $102.27 million

Beta

0.17
ADAG beta is 0.17

200-day SMA

$2.68
ADAG 200-day simple moving average is currently -13.79% below its 200-day simple moving average

14-day RSI

44.50
ADAG 14-day relative strength index is 44.50

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

+2484.03%
ADAG annual revenue is up +2484.03% over the past 3 years

Annual Revenue Estimate

$12.33 M
ADAG annual revenue is currently +46.85% higher than the consensus analysts' forecast

Annual Net Income 3-Year Change

+55.31%
ADAG annual net profit is up +55.31% over the past 3 years

Annual EPS 3-Year Change

+56.73%
ADAG annual earnings per share is up +56.73% over the past 3 years

Annual EPS Estimate

-$0.58
ADAG annual earnings per share is currently -24.57% lower than the consensus analysts' forecast

Annual Operating Profit

-$23.72 M
ADAG annual operaing income is -$23.72 million

Annual Operating Profit 3-Year Change

+45.03%
ADAG annual operaing income is up +45.03% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Operating Margin Sector Rank

40.4%
ADAG annual operating profit margin is higher than 40.4% of companies in Healthcare sector

Annual Net Margin Sector Rank

44.33%
ADAG annual net profit margin is higher than 44.33% of companies in Healthcare sector

Annual ROE

-24.66%
ADAG annual return on equity is -24.66%

Annual ROA

-14.13%
ADAG annual return on assets is -14.13%

Annual EBIT

-$16.15 M
ADAG annual earnings before interest & taxes is -$16.15 million

Annual EBITDA

-$14.94 M
ADAG annual earnings before interest, taxes, depreciation & amortization is -$14.94 million

Annual Interest Coverage Ratio

-14.58
ADAG annual interest coverage ratio is -14.58

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

51.89%
ADAG price to book ratio is higher than 51.89% of companies in Healthcare sector

Enterprise Value

$27.38 M
ADAG enterprise value is $27.38 million

Enterprise Value 1-Year Change

+167.78%
ADAG enterprise value is up +167.78% year-on-year

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

73.59%
ADAG annual debt to equity ratio is higher than 73.59% of companies in Healthcare sector

Annual Current Ratio

3.61
ADAG annual current ratio is 3.61

Annual Current Ratio Sector Rank

53.48%
ADAG annual current ratio is higher than 53.48% of companies in Healthcare sector

Annual Total Assets

$115.73 M
ADAG annual total assets is $115.73 million

Annual Current Assets

$113.44 M
ADAG annual total current assets is $113.44 million

Annual Total Liabilities

$45.17 M
ADAG annual total liabilities is $45.17 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+0.26%
ADAG annual cash flow from operations is up +0.26% over the past 3 years

Annual CFI 3-Year Change

-101.09%
ADAG annual cash flow from investing activities is down -101.09% over the past 3 years

Annual CFF 3-Year Change

-220.89%
ADAG annual cash flow from financing activities is down -220.89% over the past 3 years

Annual CAPEX

$85.00 K
ADAG annual capital expenditures is $85.00 thousand

Annual CAPEX 3-Year Change

-90.91%
ADAG annual capital expenditures is down -90.91% over the past 3 years

Annual FCF

-$28.54 M
ADAG annual free cash flow is -$28.54 million

Annual FCF 3-Year Change

+3.14%
ADAG annual free cash flow is up +3.14% over the past 3 years

Institutional Ownership

Similar stocks

NVCT logo
Nuvectis Pharma (NVCT)
OPRX logo
OptimizeRx (OPRX)
MNPR logo
Monopar Therapeutics (MNPR)
RGLS logo
Regulus Therapeutics (RGLS)
AVTX logo
Avalo Therapeutics (AVTX)
FONR logo
FONAR (FONR)
QIPT logo
Quipt Home Medical (QIPT)
MIST logo
Milestone Pharmaceuticals (MIST)
GBIO logo
Generation Bio Co (GBIO)
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
ADAG
zacks.com20 November 2024

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adagene (ADAG) This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
ADAG
zacks.com11 September 2024

Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
ADAG
globenewswire.com12 July 2024

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024.

Adagene to Present at Investor Conferences in June
Adagene to Present at Investor Conferences in June
Adagene to Present at Investor Conferences in June
ADAG
globenewswire.com22 May 2024

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024.

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
ADAG
GlobeNewsWire04 January 2024

- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
ADAG
Zacks Investment Research27 September 2023

Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adagene (ADAG) This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
ADAG
Zacks Investment Research07 September 2023

Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
ADAG
Zacks Investment Research25 May 2023

Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.

FAQ

  • What is the primary business of Adagene?
  • What is the ticker symbol for Adagene?
  • Does Adagene pay dividends?
  • What sector is Adagene in?
  • What industry is Adagene in?
  • What country is Adagene based in?
  • When did Adagene go public?
  • Is Adagene in the S&P 500?
  • Is Adagene in the NASDAQ 100?
  • Is Adagene in the Dow Jones?
  • When was Adagene's last earnings report?
  • When does Adagene report earnings?
  • Should I buy Adagene stock now?

What is the primary business of Adagene?

Adagene is a biotechnology company focused on developing innovative antibody-based therapies for cancer treatment. They use advanced technology to create personalized medicines that target specific cancer cells, aiming to improve patient outcomes and reduce side effects. Their goal is to enhance the effectiveness of cancer therapies.

What is the ticker symbol for Adagene?

The ticker symbol for Adagene is NASDAQ:ADAG

Does Adagene pay dividends?

No, Adagene does not pay dividends

What sector is Adagene in?

Adagene is in the Healthcare sector

What industry is Adagene in?

Adagene is in the Biotechnology industry

What country is Adagene based in?

Adagene is headquartered in China

When did Adagene go public?

Adagene's initial public offering (IPO) was on 09 February 2021

Is Adagene in the S&P 500?

No, Adagene is not included in the S&P 500 index

Is Adagene in the NASDAQ 100?

No, Adagene is not included in the NASDAQ 100 index

Is Adagene in the Dow Jones?

No, Adagene is not included in the Dow Jones index

When was Adagene's last earnings report?

Adagene's most recent earnings report was on 25 July 2024

When does Adagene report earnings?

The next expected earnings date for Adagene is 28 March 2025

Should I buy Adagene stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions